• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Exelixis' Cabometyx scores backing from Ipsen in thyroid cancer, with full data...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   May 12, 2021 at 11:42: PM
via Exelixis' flagship oncology drug Cabometyx has attracted a pharma partner to take it into a new type of cancer thanks to promising results in a pivotal trial.

article source
 

<



Similar threads

cafead
Combo of Roche&#039;s Tecentriq and Exelixis&#039; Cabometyx fails another trial, this time...
Replies
0
Views
113
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
In surprising flop, Exelixis&#039; Cabometyx combo with Roche&#039;s Tecentriq fails to...
Replies
0
Views
229
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Exelixis drops tissue factor-targeting ADC after deciding it&#039;s no match for Tivdak
Replies
0
Views
16
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Analysts throw cold water on Exelixis and Roche&#039;s prostate cancer data, putting the...
Replies
0
Views
243
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Exelixis Bolsters Pipeline in Deal with India&#039;s Aurigene
Replies
0
Views
171
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote